This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Not applicable	<p>Computational analysis of breast cancer samples from patients suggests therapeutic strategies used to treat ovarian cancer could help treat a class of basal-like breast tumors. Computational analysis of genomic and proteomic data from primary breast cancer samples identified basal-like breast tumors as a class with features similar to those of serous ovarian cancer. The data suggest patients with this class of breast tumors might benefit from treatment with poly(ADP-ribose)polymerase (PARP) inhibitors and/or platinum compounds used to treat serous ovarian cancer. Next steps could include clinical trials.</p> <p>Abbott Laboratories has the PARP inhibitor veliparib in Phase I and Phase II trials to treat multiple types of cancer. AstraZeneca plc has the PARP inhibitor Olaparib in Phase I testing to treat brain cancer and Phase II trials to treat solid tumors.</p> <p>BioMarin Pharmaceutical Inc. has BMN-673 in Phase I/II trials to treat hematologic malignancies and solid tumors.</p> <p>SciBX 5(41); doi:10.1038/scibx.2012.1078 Published online Oct. 18, 2012</p>	Unpatented; licensing status not applicable	<p>The Cancer Genome Atlas Network. <i>Nature</i>; published online Sept. 23, 2012; doi:10.1038/nature11412</p> <p>Contact: Charles M. Perou, The University of North Carolina at Chapel Hill, Chapel Hill, N.C. e-mail: cperou@med.unc.edu</p>